Neurogene Inc. — Director's Dealing 2019

Dec 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2019-11-12

Reporting Person: DRACHMAN JONATHAN G (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-12	Series A Preferred Stock	C	12616	$0.00	Disposed	0	Direct
2019-11-12	Common Stock	C	1261600	$0.00	Acquired	2079639	Direct
2019-12-20	Common Stock	P	119047	$8.40	Acquired	2198686	Direct

Footnotes

F1: Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019.

F2: Represents shares purchased in an underwritten public offering of the Issuer's Common Stock.